Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
MemoBoost is developing a pioneering drug treatment designed to inhibit the onset of dementia. The companys technology is based on research into the scientific foundations of learning and memory in the brain.
MemoBoost is headed by Prof. Edi Barkai of the University of Haifas Sagol Department of Neurobiology and the head of the Laboratory for Neurobiology of Learning and Memory. Prof. Barkai is on the path to developing a cognitive/learning-enhancing drug that may counter the cognitive deficits suffered by dementia patients.
Prof. Barkais research has identified a specific receptor in the brain, in the mGluR family, which inhibits learning when its excitability is blocked and improves learning when its excitability is consistently enhanced. Using a research compound that activates this receptor, Prof. Barkais group has successfully shown that learning is significantly enhanced in a validated animal model of learning.
The compound is currently being modified and tested in order to develop a drug that will serve as a potent cognitive enhancer to tackle the onset of dementia and other cognitive deficits.